ValuEngine upgraded shares of Johnson & Johnson (NYSE:JNJ) from a hold rating to a buy rating in a research report sent to investors on Thursday.
JNJ has been the topic of several other reports. Zacks Investment Research upgraded shares of Johnson & Johnson from a hold rating to a buy rating and set a $164.00 target price on the stock in a research report on Wednesday. Wells Fargo & Co reiterated an outperform rating and set a $160.00 target price (up from $155.00) on shares of Johnson & Johnson in a research report on Wednesday, October 17th. Credit Suisse Group lifted their target price on shares of Johnson & Johnson from $149.00 to $152.00 and gave the company an outperform rating in a research report on Wednesday, October 17th. Finally, Citigroup lifted their target price on shares of Johnson & Johnson from $137.00 to $148.00 and gave the company a neutral rating in a research report on Monday, October 22nd. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating and ten have given a buy rating to the stock. The stock currently has an average rating of Hold and a consensus target price of $142.58.
Shares of Johnson & Johnson stock opened at $133.00 on Thursday. The company has a current ratio of 1.72, a quick ratio of 1.40 and a debt-to-equity ratio of 0.46. Johnson & Johnson has a twelve month low of $118.62 and a twelve month high of $148.99. The stock has a market cap of $356.83 billion, a PE ratio of 16.73, a price-to-earnings-growth ratio of 2.08 and a beta of 0.59.
The company also recently declared a quarterly dividend, which was paid on Tuesday, December 11th. Shareholders of record on Tuesday, November 27th were given a $0.90 dividend. The ex-dividend date was Monday, November 26th. This represents a $3.60 dividend on an annualized basis and a yield of 2.71%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 49.32%.
In other Johnson & Johnson news, CAO Ronald A. Kapusta sold 3,643 shares of the business’s stock in a transaction dated Thursday, December 13th. The shares were sold at an average price of $147.31, for a total value of $536,650.33. Following the transaction, the chief accounting officer now directly owns 13,641 shares in the company, valued at $2,009,455.71. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, VP Peter Fasolo sold 166,695 shares of the business’s stock in a transaction dated Tuesday, December 4th. The shares were sold at an average price of $146.41, for a total transaction of $24,405,814.95. Following the completion of the transaction, the vice president now owns 155,540 shares in the company, valued at $22,772,611.40. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 514,187 shares of company stock worth $74,951,528. Company insiders own 0.22% of the company’s stock.
A number of large investors have recently added to or reduced their stakes in JNJ. Financial Gravity Wealth Inc. bought a new position in shares of Johnson & Johnson in the first quarter worth about $105,000. Selective Wealth Management bought a new position in shares of Johnson & Johnson in the third quarter worth about $105,000. WP Advisors LLC bought a new position in shares of Johnson & Johnson in the second quarter worth about $108,000. FNY Investment Advisers LLC bought a new position in shares of Johnson & Johnson in the second quarter worth about $117,000. Finally, Fusion Family Wealth LLC raised its stake in shares of Johnson & Johnson by 621.4% in the second quarter. Fusion Family Wealth LLC now owns 1,010 shares of the company’s stock worth $123,000 after acquiring an additional 870 shares during the last quarter. Hedge funds and other institutional investors own 66.45% of the company’s stock.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.
Featured Story: Understanding Compound Annual Growth Rate (CAGR)
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.